Landmark Victory For Ripple and the Entire Crypto Industry in SEC Lawsuit
20.7.2023 00:57:00 EEST | Business Wire | Press release
From day one, Ripple has said the SEC's suit against the company (and its CEO and Chair) was baseless and yet another attempt to regulate through intimidation and enforcement. The Court’s July 13 decision is a landmark ruling, not just for Ripple, but for the entire U.S. crypto industry.
This case was always about one thing and one thing only: whether XRP, a crypto token, could be an investment contract and therefore a security under the law. The Court unequivocally said that XRP, as a digital token, is not in and of itself a security. Last week’s ruling makes clear that the SEC’s misguided theory - that crypto tokens standing alone are securities - has no support in the law.
"The Court's decision marks a historic occasion not only for the company, but also for crypto at large," said Ripple CEO Brad Garlinghouse. "We’ve said since the earliest days of the lawsuit that Ripple would be on the right side of the law, and the right side of history. Progress is worth fighting for. This decision is a significant blow to the agency's regulation by enforcement agenda, and I hope we will soon look back at this decision as the turning point for Congress to act and set clear rules of the road for crypto in the U.S."
In addition, the Court found that, as a matter of law:
- Ripple’s XRP sales on exchanges – not securities.
- XRP sales by Ripple executives – not securities.
- Ripple’s XRP distributions to developers, to charities, and to employees – not securities.
“In its ruling, the Court distinguished between the token itself, and the manner in which it was sold declaring XRP, in and of itself, is not an investment contract. This decision will have profound consequences on how digital tokens are classified in the U.S. moving forward," said Ripple Chief Legal Officer Stu Alderoty. "The Court’s ruling can now be used by others in the agency’s crosshairs. The SEC can no longer tout their record in crypto – which was, up until now, by and large settlements with players that didn’t have the resources or conviction to fight back.”
Further Court proceedings are only on certain contractual sales to institutional investors (the Court determined those contracts to be securities, not the token itself) per the Court’s order. Everything else is settled as a matter of law.
Ripple's pursuit of sound crypto regulation in the U.S. is far from concluded; in fact, it is just the beginning. In the meantime, Ripple will continue to invest in jurisdictions that have embraced clear regulatory frameworks. Last month, the Monetary Authority of Singapore granted Ripple an In-Principle Approval (IPA) for a Major Payments Institution License. Multiple foreign regulators, including those in Japan, Switzerland, the UAE and the UK, had already determined that XRP was not a security.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719136007/en/
Contact information
Stacey Ngo
Press@ripple.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg
Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release
Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
